Regeneron Pharmaceuticals financials
$750.51−0.23%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.29B | $3.61B | $3.88B | $3.75B | $3.68B | $3.03B | $3.79B | $3.72B | $3.55B | $3.15B | $3.43B | $3.36B |
| Gross profit | $3.71B | $2.94B | $3.30B | $3.23B | $3.15B | $2.56B | $3.22B | $3.23B | $3.29B | $2.71B | $2.92B | $2.93B |
| Gross margin | 86.6% | 81.4% | 84.9% | 86.1% | 85.6% | 84.7% | 85.1% | 86.8% | 92.7% | 86.2% | 84.9% | 87.0% |
| Operating income | $1.29B | $642.9M | $869.9M | $1.03B | $1.08B | $591.7M | $1.04B | $1.18B | $1.07B | $751.4M | $972.9M | $1.11B |
| Net income | $1.30B | $727.2M | $844.6M | $1.46B | $1.39B | $808.7M | $917.7M | $1.34B | $1.43B | $722.0M | $1.16B | $1.01B |
| Net margin | 30.2% | 20.2% | 21.7% | 38.9% | 37.9% | 26.7% | 24.2% | 36.0% | 40.4% | 23.0% | 33.8% | 30.0% |
| Diluted EPS | $12.23 | $6.75 | $7.86 | $13.62 | $12.81 | $7.27 | $8.07 | $11.54 | $12.41 | $6.27 | $10.22 | $8.89 |
| EBITDA | $1.42B | $766.1M | $1.01B | $1.16B | $1.21B | $718.6M | $1.17B | $1.30B | $1.19B | $865.5M | $1.09B | $1.22B |
| Operating cash flow | $813.0M | $1.08B | $1.17B | $1.62B | $1.14B | $1.05B | $1.26B | $1.29B | $354.0M | $1.51B | $1.09B | $1.11B |
| Free cash flow | $572.8M | $848.3M | $922.0M | $1.42B | $925.4M | $815.8M | $1.06B | $1.05B | $173.5M | $1.38B | $838.3M | $938.3M |
| Diluted shares | 106.0M | 107.7M | 107.4M | 107.2M | 108.6M | 111.2M | 113.7M | 116.2M | 115.4M | 115.1M | 113.5M | 113.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.46B | $2.96B | $3.12B | $2.51B | $2.00B | $3.09B |
| Short-term investments | $5.54B | $5.79B | $5.49B | $5.94B | $5.47B | $5.26B |
| Total debt | $2.71B | $2.71B | $2.71B | $2.71B | $2.71B | $2.70B |
| Total assets | $41.73B | $40.87B | $40.56B | $40.17B | $38.22B | $37.55B |
| Total liabilities | $10.02B | $9.45B | $9.30B | $9.21B | $8.28B | $8.16B |
| Shareholders' equity | $31.71B | $31.42B | $31.26B | $30.96B | $29.94B | $29.39B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology